Midkine (MK), Human BioAssay(TM) ELISA Kit

In the Human Midkine ELISA, Calibrators, Quality Controls, and samples are incubated with a rabbit polyclonal anti-human midkine antibody coated in microtiter wells. After two hours of incubation and washing, biotin-labeled polyclonal anti-human midkine antibody is added and incubated with captured midkine for one hour. After a thorough wash, streptavidin-horseradish peroxidase conjugate is added. After one hour of incubation and the last washing step, the remaining conjugate is allowed to react with the substrate H2O2-tetramethylbenzidine. The reaction is stopped by the addition of acidic solution and the absorbance of the resulting yellow product is measured at 450nm. The absorbance is proportional to the concentration of midkine. A standard curve is constructed by plotting the absorbance values against the concentrations of midkine calibrators. The concentrations of unknown samples are determined using this standard curve.\n\nSamples: serum, citrate plasma and heparin plasma.\n\nKit Components:\nM3896-04B: Microtiter Plate, 1x96 wells\nM3896-04C: Midkine Antibody (Biotin) 1x13ml \nM3896-04D: Streptavidin (HRP) 1x13ml\nM3896-04E: Human Standard, 2x1vial\nM3896-04F: Quality Control 1x1vial\nM3896-04J: Wash Solution, 10x 1x100ml \nM3896-04K: Substrate Solution (TMB), 1x13ml\nM3896-04L: Stop Solution, H2SO4, 1x13ml\nM3896-04M: Dilution Buffer 1x13ml\nM3896-04N: Standard Diluent: 1x9ml\n\nStorage and Stability:\nStore all components at 4C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Reconstituted standards and controls can be aliquoted and stored at -20C..

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M3896-04

Size

1Kit

Applications

ELISA

Reactivities

Hum

References

1. Choudhuri R., et al., Cancer Res. 57, 1814-1819. (1997). 2. Ye, C., et al., Brit. J. Cancer 79, 179-184. (1999). 3. Konishi, N., et al., Oncology 57,253-257. (1999). 4. Ohta, S., et al., J. Bone Miner. Res. 14, 1132-1144. (1999). 5. Ikematsu, S., et al., Brit. J. Cancer. 83, 701-706. (2000). 6. Callebaut, C., et al., Virology 281, 248-264. (2001). 7. Sato, W., et al., J. Immunol. 167, 3463-3469. (2001). 8. Shimada, H., et al., Oncol. Rep. 10, 411-414. (2003). 9. Ikematsu, S., et al., Br. J. Cancer 88, 1522-1526. (2003). 10. Ikematsu, S., et al., Biochem. Biophys. Res. Commun. 306, 329-332. (2003). 11. Maruyama, K., et al., Arthritis Rheum. 50, 1420-1429. (2004). 12. Obata, Y., et al., Cancer Sci. 96, 54-56 (2005).